Celadon Pharmaceuticals PLC (CEL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celadon Pharmaceuticals PLC (CEL) has a cash flow conversion efficiency ratio of -0.525x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.29 Million ≈ $-156.59 USD) by net assets (GBX2.45 Million ≈ $298.46 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Celadon Pharmaceuticals PLC (CEL) defensive interval to measure how many days the company can operate on defensive assets alone.
Celadon Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Celadon Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Celadon Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celadon Pharmaceuticals PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WORK Medical Technology Group LTD Ordinary Shares
NASDAQ:WOK
|
0.427x |
|
Croma Security Solutions Group Plc
LSE:CSSG
|
0.033x |
|
Block Energy PLC
LSE:BLOE
|
0.007x |
|
Cadogan Petroleum plc
LSE:CAD
|
-0.008x |
|
Rockfire Resources plc
LSE:ROCK
|
-0.092x |
|
Induction Healthcare Group PLC
LSE:INHC
|
-0.052x |
|
Ceps PLC
LSE:CEPS
|
0.229x |
|
Stora Enso Oyj ser. R
ST:STE-R
|
0.015x |
Annual Cash Flow Conversion Efficiency for Celadon Pharmaceuticals PLC (2019–2023)
The table below shows the annual cash flow conversion efficiency of Celadon Pharmaceuticals PLC from 2019 to 2023. For the full company profile with market capitalisation and key ratios, see CEL market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | GBX3.18 Million ≈ $387.04 |
GBX-5.97 Million ≈ $-726.62 |
-1.877x | -116.58% |
| 2022-12-31 | GBX7.04 Million ≈ $856.20 |
GBX-6.10 Million ≈ $-742.19 |
-0.867x | -76.53% |
| 2021-12-31 | GBX6.41 Million ≈ $780.00 |
GBX-3.15 Million ≈ $-383.02 |
-0.491x | +37.31% |
| 2020-12-31 | GBX99.03K ≈ $12.05 |
GBX-77.57K ≈ $-9.44 |
-0.783x | -4386.83% |
| 2019-12-31 | GBX-113.47K ≈ $-13.81 |
GBX1.98K ≈ $0.24 |
-0.017x | -- |
About Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.